Log in

NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News

+0.12 (+0.80 %)
(As of 06/4/2020 04:00 PM ET)
Today's Range
Now: $15.10
50-Day Range
MA: $16.42
52-Week Range
Now: $15.10
Volume770,257 shs
Average Volume1.54 million shs
Market Capitalization$1.70 billion
P/E RatioN/A
Dividend YieldN/A
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Read More
Aurinia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AUPH



Sales & Book Value

Annual Sales$320,000.00
Book Value$2.45 per share


Net Income$-123,850,000.00
Net Margins-43,965.98%


Market Cap$1.70 billion
Next Earnings Date8/4/2020 (Estimated)

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

How has Aurinia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has increased by 7.1% and is now trading at $15.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.05. The biotechnology company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%. View Aurinia Pharmaceuticals' earnings history.

What price target have analysts set for AUPH?

8 analysts have issued 1 year price targets for Aurinia Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $24.29 in the next twelve months. This suggests a possible upside of 60.8% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News headlines about AUPH stock have trended very negative on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutAurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 4,740,000 shares, a drop of 5.0% from the April 15th total of 4,990,000 shares. Based on an average trading volume of 1,540,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 5.5% of the company's shares are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Alibaba Group (BABA), Exelixis (EXEL), Novavax (NVAX) and Corbus Pharmaceuticals (CRBP).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pictet Asset Management Ltd. (1.44%), Orbimed Advisors LLC (1.19%), Franklin Resources Inc. (1.12%), Connor Clark & Lunn Investment Management Ltd. (0.96%), Assenagon Asset Management S.A. (0.89%) and BlackRock Inc. (0.83%).

Which major investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ghost Tree Capital LLC, Creative Planning, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., Franklin Resources Inc., and Toronto Dominion Bank.

Which major investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., Vivo Capital LLC, Wells Fargo & Company MN, Lord Abbett & CO. LLC, Atom Investors LP, and Two Sigma Advisers LP.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $15.10.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $1.70 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.